ExThera Medical: The Warning Came Before the Deaths

Under the ExThera Medical deferred prosecution agreement, the company admitted that, through its former chief regulatory officer, it acted with intent to defraud and mislead the Food and Drug Administration. The criminal case concerned a blood-filtration device used on cancer patients at a clinic in Antigua, including two patients who died. Before treatment began, the chief regulatory officer had circulated an internal warning about possible life-threatening complications. The risk had reached company leadership before the deaths reached FDA.

The Justice Department announced the agreement on March 5, 2026. For someone working in device safety or regulatory affairs, the decisive part of this story is the distance between what the company knew and what it reported.

What Happened at the Antigua Clinic

ExThera manufactured a device that filtered pathogens from a patient’s bloodstream. Cancer patients traveled from the United States to receive treatment with it in Antigua.

According to the Massachusetts charging announcement, the chief regulatory officer circulated an email to ExThera’s leadership and regulatory staff before treatments started. The email demonstrated awareness of potential adverse events, including complications that could threaten patients’ lives.

The Justice Department’s account of the criminal case describes what happened next. Some patients and their treating physicians reported that they believed patients had experienced some of those medical events after treatment. In March and April 2024, the officer learned of the declining health and deaths of at least two patients at the clinic. They died within days of each other.

For an insider, the email and the later patient reports tell different parts of the same story: what the company understood about the risk, and what it learned when patients actually received treatment.

The Financial Stakes Behind the Reporting Decision

ExThera had just secured $10 million when the Antigua clinic began treating patients, according to the Justice Department’s account of the court documents. Future distribution agreements offered the prospect of millions more. The chief regulatory officer was also overseeing the company’s first U.S. clinical study using the device to treat cancer.

The government alleged that the officer understood what adverse-event reports could set in motion: scrutiny from the Food and Drug Administration, withdrawal by clinical trial partners and damage to the company’s and the officer’s financial prospects. It alleged that the officer suppressed the information instead of reporting it.

Patients and their physicians were reporting medical problems while the company had money and research partnerships to protect. The officer responsible for reporting the risk, the government alleged, also understood what disclosure could cost the business.

Why the FDA Reports Came Later

ExThera filed several adverse-event reports with the Food and Drug Administration after public reporting about the device and after it terminated the chief regulatory officer, according to both Justice Department announcements. Those reports concerned use of the device to treat cancer outside the United States. The Justice Department also said ExThera did not voluntarily and promptly disclose the conduct to it.

The warning email, the information coming back from the clinic and the eventual submissions give an insider concrete places to connect awareness with the reporting decision.

The events occurred abroad, but the criminal charge concerned information withheld from the Food and Drug Administration by a Northern California device company.

What ExThera Admitted Under the Agreement

ExThera admitted intent to defraud and mislead the Food and Drug Administration through its former officer under a three-year deferred prosecution agreement. The corporate charge concerned failure to file adverse-event reports with that intent.

The district announcement describes a compliance program aimed at preventing adverse-event reporting violations, with reports to the Justice Department on remediation and implementation. The agreement put the reporting function at the center of the company’s required changes.

The company responsible for telling the regulator about the events had a financial interest in keeping them quiet.

The Reporting Decision Inside a Device Company

In ExThera’s case, an employee who knows how the warning email and later patient reports were handled can explain a part of the company’s conduct that an eventual submission alone would leave out.

What Internal Complaint Files Can Show

The whistleblower complaint against Alere San Diego alleged that internal complaints about a Triage assay revealed problems barely reflected in public adverse-event reports for the panel.

Magellan Diagnostics and the Information Customers Discovered

According to the Justice Department’s account of the criminal case, Magellan Diagnostics changed its testing instructions after customers discovered inaccurate blood-lead results, before reporting the malfunction and changed instructions to the Food and Drug Administration.

What Evidence Is Needed to Prove Fraud?

For a civil medical device fraud case, the evidence needs to connect what the manufacturer knew and did with a false request for government payment. We examine that connection with insiders who know the product, the safety records or the decisions behind its use.

The 2020 Journal of Forensic and Investigative Accounting paper A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud explains that a healthcare payment request can go to another organization while federal funds pay all or part of the bill. That makes the payment trail worth following beyond the manufacturer’s own sales records.

In device work, that means connecting the manufacturer’s conduct with the treatment and billing records. Food and Drug Administration marketing authorization, Medicare coverage, billing codes and the amount paid each answer different questions. A quality specialist may understand the complaint history, while someone involved in clinical use or reimbursement understands how the device reached a patient and a government-funded claim. We work with the insider to establish how those pieces fit.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What Reached the Reporting Desk

If you saw safety information held back while a device business protected its funding or clinical relationships, speak to one of our Whistleblower Experts about the reports that never reached FDA. We build your strongest medical device whistleblower case with you, find medical device fraud whistleblower lawyers who understand quality and regulatory records, and stay beside you throughout the case.